Clinical Outcomes after Treatment of Periodontal Intrabony Defects with Nanocrystalline Hydroxyapatite (Ostim) or Enamel Matrix Derivatives (Emdogain): A Randomized Controlled Clinical Trial
Figure 5
Distribution (%) of early wound-healing index at the treated sites, at 1 and 2 weeks after treatment. No significant differences between groups (7 days: ; 14 days: , Mann-Whitney U test) EMD: enamel matrix derivate; NHA: nanocrystalline hydroxyapatite.
